| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Theriva Biologics, Inc.$0.24
0 (-0.77%)
C 48Pipeline Score Fair Value Pharma · Clinical
Market Cap
14.41 M
EPS
-2.53
P/E Ratio
-
Value Trade
156.90 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
300.00 K
R&D Expenses
355.00 K
Operating CF
-2.46 M
Total Assets
38.25 M
Total Liabilities
22.85 M
Equity
15.40 M
D/E Ratio
12,345
-1.88 %
Week
-1.91 %
1 Month
68.55 %
3 Month
50.24 %
6 Month
-99.76 %
5 Year
-100 %
All Time
Cash Data
Cash Position
14.43 M
Monthly Burn
819.00 K
Runway
15.6 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
1.17 M
52 Week Range
0.16 - 0.86
% held by Insiders
1.63 %
% held by Institutions
4.28 %
Enterprise Value
3.67 M
Total Shares
45.88 M
Short %
6.56 %
Float Shares
45.42 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Theriva Biologics, Inc.
699Total events
7Upcoming
157Tier-1 (high impact)
2007 – 2029Coverage
Upcoming catalysts 7
Dec 2026
T2First Patient Dosed
First patient enrollment expected in Phase 2/3 retinoblastoma trial in December 2026
TBD
T2Equity Offering
Seeking financing and/or partnerships to execute planned pivotal trial programs
TBD
T2Timing Guidance
Company finalizing pivotal trial design for VCN-01 in retinoblastoma for regulatory discussion
TBD
T3Manufacturing Milestone
Avances para aumentar producción de VCN-01 con línea celular en suspensión
TBD
T1Partnership / License
Estrategia de divulgación para identificar posibles socios para desarrollo clínico en fase avanzada
Event history 692
Jul 7, 2026
▲Trial InitiationVCN-01ApprovedTrial
Regulatory authorization to initiate VIRAGE2 Phase 2a trial of VCN-01 in first-line metastatic PDAC
metastatic pancreatic ductal adenocarcinomasource ↗
Jul 7, 2026
▲FDA Feedback ReceivedVCN-01ApprovedFDA Meeting
FDA recognized potential of repeated VCN-01 dosing from VIRAGE trial
metastatic pancreatic ductal adenocarcinomasource ↗
Jul 7, 2026
▲EU MAA SubmissionVCN-01ApprovedEx-US Regulatory
EMA recognized potential of repeated VCN-01 dosing from VIRAGE trial
metastatic pancreatic ductal adenocarcinomasource ↗
Jul 7, 2026
▲Topline ReadoutVCN-01ApprovedClinical Data
VIRAGE Phase 2b topline results: 2 doses of VCN-01 improved OS, PFS, and DOR vs 1 dose or SoC alone
metastatic pancreatic ductal adenocarcinomasource ↗
Q3 2026
◆Trial InitiationVCN-01ApprovedTrial
Dosing feasibility study (Phase 2a) expected to commence in Spain in 2H 2026
metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
Jun 11, 2026
▲Full ResultsVCN-01ApprovedClinical Data
Results from VCN-01 Phase 1 clinical trial in HNSCC published in Clinical Cancer Research
Head & Neck Squamous Cell Carcinoma (HNSCC)source ↗
Apr 20, 2026
◆Poster PresentationVCN-01ApprovedPresentation
Poster presentation of tumor response, biomarker, and subgroup analyses from VIRAGE Phase 2b trial at AACR 2026
metastatic pancreatic cancersource ↗
Apr 17, 2026
◆Poster PresentationVCN-01ApprovedPresentation
Additional analysis from VIRAGE Phase 2b accepted for poster at AACR 2026
pancreatic ductal adenocarcinomasource ↗
Apr 2026
▲Poster PresentationVCN-01ApprovedPresentation
Additional data from VIRAGE Phase 2b presented at AACR 2026
metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
Q1 2026
▲End Of Phase 2 MeetingVCN-01ApprovedFDA Meeting
FDA End-of-Phase 2 meeting minutes received, alignment on Phase 3 trial design
metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
Mar 23, 2026
▲End Of Phase 2 MeetingVCN-01ApprovedFDA Meeting
Positive End-of-Phase 2 meeting with FDA regarding Phase 3 trial design for VCN-01 in metastatic PDAC
metastatic pancreatic ductal adenocarcinomasource ↗
Drug Pipeline Intelligence
C48
Pipeline Score $28M
Pipeline ValueFair Value
Valuation Signal5
Drugs Scored1.9x
rNPV / MCap Top 72%
Micro Cap (rank 256 of 911)
Percentile RankTheriva Biologics, Inc. carries a moderate pipeline score (48/100), with $2.2B risk-adjusted pipeline value, led by VCN-01 in Locally Advanced Solid Tumors (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VCN-01 Monoclonal antibody | Pancreatic Cancer | Phase 1 | NCT05057715 | 57% | $1.6B | ACTIVE NOT_RECRUITING | 13 | - | - | Sep 1, 2038 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VCN-01 Fast TrackOrphanRare Pediatric | Head & Neck Squamous Cell Carcinoma | Phase 1 | 2026-06-11 | median overall survival: Arm I LD 10.3 months, Arm II LD 15.5 months, Arm II HD 17.3 months; median progression free survival: Arm I LD 1.6 months, Arm II LD 3.7 months, Arm II HD 2.1 months; circulating levels of PH20: increased significantly after VCN-01 administration, peaking on day 3-8 for most patients and detectable until day 28 in 11 of 12 patients. Read More | Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research Read More | |
VCN-01 Fast TrackOrphanRare Pediatric | Head & Neck Squamous Cell Carcinoma | Phase 1 | 2026-06-11 | median overall survival: Arm I LD 10.3 months, Arm II LD 15.5 months, Arm II HD 17.3 months; median progression free survival: Arm I LD 1.6 months, Arm II LD 3.7 months, Arm II HD 2.1 months; circulating levels of PH20: increased significantly after VCN-01 administration, peaking on day 3-8 for most patients and detectable until day 28 in 11 of 12 patients. Read More | Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research Read More | |
VCN-01 Fast TrackOrphanRare Pediatric | Head & Neck Squamous Cell Carcinoma | Phase 1 | 2026-06-11 | median overall survival: Arm I LD 10.3 months, Arm II LD 15.5 months, Arm II HD 17.3 months; median progression free survival: Arm I LD 1.6 months, Arm II LD 3.7 months, Arm II HD 2.1 months; circulating levels of PH20: increased significantly after VCN-01 administration, peaking on day 3-8 for most patients and detectable until day 28 in 11 of 12 patients. Read More | Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TOVX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TOVX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TOVX▼ -7.1%on this news
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Theriva Biologics has received regulatory approval from the Spanish Agency of Medicines to initiate the VIRAGE2 Phase 2a clinical trial. This trial will explore more frequent dosing of VCN-01 in combination with standard chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma. The study aims to refine the dosing regimen based on positive outcomes from earlier trials.
Read more →TOVX▲ +26.1%on this news
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
Theriva Biologics announced positive results from its Phase 1 trial of VCN-01 in patients with refractory Head & Neck Squamous Cell Carcinoma (HNSCC). The study demonstrated prolonged overall survival and enhanced immune responses when VCN-01 was administered prior to durvalumab. Key findings include increased levels of PD-L1 positive T-cells and significant pharmacokinetic results supporting VCN-01's mode of action.
Read more →TOVX▲ +26.1%on this news
Theriva™ Biologics anuncia los resultados del ensayo clínico de Fase I con VCN-01 para el cáncer de cabeza y cuello, publicados en la revista *Clinical Cancer Research*
Theriva™ Biologics announced positive results from its Phase I trial of VCN-01 for refractory head and neck squamous cell carcinoma (HNSCC). The study demonstrated prolonged overall survival and supported the drug's mechanisms of action, including immune response enhancement. The findings have been published in *Clinical Cancer Research*, highlighting the potential for VCN-01 in combination with immune checkpoint inhibitors.
Read more →TOVXTheriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
Theriva Biologics reported positive operational highlights for Q1 2026, including FDA alignment on the Phase 3 trial design for VCN-01 in metastatic PDAC. Data from the VIRAGE Phase 2b trial suggests improved patient outcomes, particularly in those with liver metastases. The company is also exploring compassionate use of VCN-01 for retinoblastoma patients, aiming to initiate a Phase 2/3 trial soon.
Read more →TOVX▲ +59.4%on this news
Theriva Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting - Tumor reponse, biomarker, and subgroup
Theriva Biologics has announced an upcoming presentation of new data from its VIRAGE Phase 2b clinical trial for VCN-01 in metastatic pancreatic cancer, to be held at the AACR Annual Meeting in April 2026. The data indicates improved outcomes across several patient subgroups, including those with liver metastases. This presentation will emphasize an immune-mediated mode of action for VCN-01, reinforcing confidence in its potential when combined with chemotherapy. The company has also secured alignment with regulatory agencies on plans for a pivotal Phase 3 trial to evaluate VCN-01 further.
Read more →TOVXTheriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
Theriva™ Biologics has announced the upcoming presentation of additional data from the VIRAGE Phase 2b clinical trial evaluating VCN-01 for metastatic pancreatic cancer at the AACR 2026 Annual Meeting. The data indicates improved outcomes in patients treated with VCN-01 alongside chemotherapy, reinforcing the drug's immune-mediated action. The company has also confirmed alignment with regulatory bodies on a planned Phase 3 trial, while contemplating a smaller study to boost treatment efficacy. The results could significantly impact future treatment options for this patient population.
Read more →TOVX▲ +8.4%on this news
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
Theriva Biologics has successfully concluded an End-of-Phase 2 meeting with the FDA, receiving approval for the design of a Phase 3 trial for VCN-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC). The trial aims to build on positive results from the VIRAGE Phase 2 trial, which showed improved survival rates. The FDA's feedback allows Theriva to finalize the trial protocol and seek funding opportunities.
Read more →TOVXTheriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2025
Theriva Biologics reported its financial results for the year ending December 31, 2025, highlighting advancements in its clinical pipeline, particularly for VCN-01 targeting pancreatic cancer and retinoblastoma. The company successfully licensed SYN-020 to Rasayana Therapeutics, which could yield up to $38 million in milestones. Financially, Theriva holds $15.2 million in cash, ensuring liquidity until early 2027.
Read more →TOVXTheriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
Theriva Biologics reported its full-year 2025 operational highlights and financial results, showcasing advancements in its oncology pipeline, particularly with VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma. The company successfully licensed SYN-020 to Rasayana Therapeutics, which could yield up to $38 million in milestones. Financially, Theriva has increased its cash reserves to $15.2 million, ensuring operational funding into Q1 2027.
Read more →TOVX▲ +6.3%on this news
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
Theriva Biologics has licensed SYN-020 to Rasayana Therapeutics, receiving an upfront payment of $300,000 and the potential for up to $38 million in milestones. Rasayana will take on all development and commercialization responsibilities for SYN-020, which has shown promise in addressing gastrointestinal dysfunction and related health issues. The drug is set to enter Phase 2 clinical testing.
Read more →TOVXTheriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
Theriva Biologics announced that it will present data from its Phase 1 clinical trial of VCN-01 for refractory retinoblastoma at the APAO Congress in February 2026. The study evaluates the safety and efficacy of VCN-01 in pediatric patients who have not responded to standard treatments. Additionally, preclinical data will showcase the potential benefits of combining VCN-01 with topotecan, a standard chemotherapy.
Read more →TOVXTheriva™ Biologics anuncia la próxima presentación de los datos del ensayo clínico de Fase 1 del VCN-01 para el retinoblastoma en el Congreso de la Academia de Oftalmología de Asia-Pacífico (APAO) de 2026
Theriva Biologics will present Phase 1 clinical trial results for VCN-01 at the APAO Congress in 2026. The study focuses on pediatric patients with refractory retinoblastoma. Preclinical data will also highlight the synergistic antitumor activity of VCN-01 combined with topotecan. This research aims to address significant unmet medical needs in treating this rare cancer.
Read more →TOVXUnique Oncolytic Virus Therapies for Multiple Solid Tumors January 2026 2 FORWARD LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform
Theriva Biologics is preparing for a Phase 3 clinical trial of its lead candidate, VCN-01, which targets pancreatic cancer and has demonstrated potential in treatment alongside chemotherapy. The company aims to leverage unique oncolytic virus therapy to achieve improved clinical outcomes for various solid tumors. However, the path forward includes potential risks, such as regulatory approval challenges and the need to meet patient enrollment and trial milestones on time. Overall, there exists optimism regarding VCN-01's capabilities, especially in the context of its promising early clinical data.
Read more →TOVXTheriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Theriva Biologics has received positive scientific advice from the EMA regarding the design of a Phase 3 trial for VCN-01 in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma. The EMA agreed on key trial aspects, including sample size and adaptive design. The company plans to finalize the trial protocol and has sufficient funding until Q1 2027 to support its regulatory activities.
Read more →TOVXTheriva™ Biologics anuncia el asesoramiento científico favorable de la Agencia Europea de Medicamentos (EMA) sobre el diseño de un ensayo de fase III de VCN-01 en el adenocarcinoma ductal pancreático (ACDP) metastásico
Theriva Biologics announced favorable scientific advice from the EMA regarding the Phase III trial design for VCN-01 in combination with gemcitabine/nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma. The trial will utilize an adaptive design to optimize timelines and outcomes. The company plans to meet with the FDA in 2026 to finalize a pivotal multinational Phase III trial protocol. Positive results from previous trials indicate a potential increase in patient survival.
Read more →TOVX▼ -7.7%on this news
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2025
Theriva Biologics reported its Q3 2025 financial results, highlighting the successful completion of the Phase 2b VIRAGE trial for VCN-01 in metastatic pancreatic ductal adenocarcinoma. The company presented preclinical data for VCN-12 at recent medical congresses. With $15.5 million in cash post-capital raise, Theriva is positioned to advance its regulatory and clinical strategies, although additional funding will be necessary for future trials.
Read more →TOVX▲ +8%on this newsshared move
Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results
Theriva Biologics reported operational highlights and financial results for Q3 2025, emphasizing progress in its oncology pipeline, particularly with VCN-01 in metastatic pancreatic cancer. The company successfully completed the VIRAGE Phase 2b trial and is pursuing regulatory discussions for a Phase 3 study. Financially, cash reserves have increased to $15.5 million, extending their operational runway into early 2027.
Read more →TOVX▼ -35.7%on this news
Theriva Biologics Provides Response to Unusual Market Action
Theriva Biologics has reported unusual trading activity in its stock but believes no corrective actions are needed. The company confirmed that there are no undisclosed material developments. Recently, it presented expanded data from its VIRAGE trial at the ESMO 2025 Annual Congress, highlighting its ongoing research efforts.
Read more →TOVX▼ -20.9%on this news
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. R.Garcia - Carbonero VIRAGE trial: randomized Phase IIb, open - label, study of Nab - Paclitaxel and Gemcit
The VIRAGE trial is a randomized Phase IIb study evaluating VCN-01 in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer. The trial aims to determine overall survival and other effectiveness measures compared to standard care alone. Results from a Phase 1 study indicated an acceptable safety profile and encouraging activity, suggesting VCN-01 could enhance treatment outcomes. The study will enroll 92 patients to assess its efficacy and safety further.
Read more →TOVXTheriva™ Biologics anuncia una operación de incentivo de warrants por un importe bruto de 4 millones de dólares
Theriva Biologics has announced a warrant incentive operation to raise approximately $4 million by allowing current institutional investors to exercise warrants at a reduced price. The operation aims to bolster working capital and will close around October 17, 2025. Investors will receive new warrants in exchange for exercising their current warrants, enhancing the company's financial position.
Read more →TOVX▼ -48.7%on this news· ran to -64% by day 3shared move
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
Theriva Biologics has announced a warrant inducement transaction that will generate approximately $4.0 million in gross proceeds. This agreement allows existing institutional investors to exercise warrants for common stock at a reduced price. The funds will be used for working capital and other corporate needs, with the transaction expected to close on October 17, 2025.
Read more →TOVXTheriva™ Biologics Announces Upcoming Presentations at Medical Meetings
Theriva Biologics announced upcoming presentations at ESMO 2025 and IDWeek 2025, showcasing expanded data from the VIRAGE Phase 2b trial for VCN-01 and interim safety data for SYN-004. These presentations aim to highlight the company's advancements in cancer therapeutics and microbiome protection. The focus on significant clinical data reflects the company's commitment to addressing unmet medical needs.
Read more →TOVXTheriva™ Biologics anuncia próximas ponencias en congresos médicos
Theriva Biologics has announced upcoming presentations at ESMO 2025 and IDWeek 2025. They will showcase expanded data from the VIRAGE trial on VCN-01 and preliminary safety and pharmacokinetics data for SYN-004. These presentations highlight the company's commitment to developing innovative therapies for cancer and related diseases.
Read more →TOVX▼ -14.6%on this newsshared move
Virotherapy with armed OAd Declaration of Interest: Honoraria, shares and funding from Theriva Biologics. Nab-placlitaxel+gemcitabine weekly until progression RECIST VCN-01 (1E13vp iv) Transient and mild AEs: fever, naus
New findings suggest that VCN-12, a modified oncolytic adenovirus, exhibits superior tumor cytotoxicity and immunogenicity compared to its predecessor, VCN-01, particularly in models of pancreatic cancer. In studies involving hamsters, VCN-12 not only improved survival rates but also induced complete tumor responses and long-lasting immune reactions. The modifications in VCN-12 include the incorporation of a pore-forming toxin, enhancing its therapeutic potential against tumors. The results highlight the promising role of VCN-12 in cancer treatment.
Read more →TOVXTheriva™ Biologics anuncia la presentación del VCN-12, un adenovirus oncolítico de nueva generación, en el 32.º Congreso Anual de la Sociedad Europea de Terapia Génica y Celular (ESGCT)
Theriva Biologics announced the upcoming presentation of VCN-12, a next-generation oncolytic adenovirus, at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Sevilla, Spain. The preclinical data suggests a novel mechanism of action that could enhance anti-tumor effects. Additionally, a recent monograph discusses the viability of VCN-01 for treating brain tumors.
Read more →TOVXTheriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Theriva Biologics announced a presentation at the ESGCT Congress, showcasing VCN-12, a next-generation oncolytic adenovirus. The preclinical data highlights its novel mechanism aimed at enhancing antitumor effects. Additionally, a monograph discusses VCN-01's potential for treating brain tumors through intracranial administration, emphasizing the urgent need for new therapies in this area.
Read more →TOVX▲ +14%on this news
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2025
Theriva™ Biologics reported positive preliminary results from its Phase 2b VIRAGE study of VCN-01, which demonstrated efficacy in metastatic pancreatic cancer. The company plans to present expanded data at the ESMO Congress in October 2025. Financially, Theriva has $12.1 million in cash, ensuring operational liquidity until early 2026. However, administrative expenses have surged significantly due to the costs associated with clinical trials.
Read more →TOVX▲ +14%on this news
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
Theriva Biologics reported positive topline results from the VIRAGE Phase 2b study of VCN-01, demonstrating its effectiveness in metastatic pancreatic cancer. The company plans to present expanded data at the ESMO 2025 Congress and is preparing for a potential Phase 3 trial. Financially, Theriva has $12.1 million in cash, expected to support operations into Q1 2026.
Read more →TOVXP - 161: A PHASE I DOSE - ESCALATION STUDY TO ASSESS THE ONCOLYTIC VIRUS VCN - 01 SAFETY AND EFFICACY IN REFRACTORY RETINOBLASTOMA PATIENTS Jaume Catal - Mora1,*, Jaume Mora 1,2 , Margarida Simao 1 , Francis Munier 3 , L
A Phase I dose-escalation study is underway to assess the safety and efficacy of the oncolytic virus VCN-01 for treating refractory retinoblastoma in children aged 1 to 12. Patients with intraocular retinoblastoma who previously failed conservative therapies were administered intravitreal injections of VCN-01. Early results show a well-tolerated safety profile with uveitis being the most common adverse effect and promising initial responses to the treatment. No retinal toxicity was observed, making VCN-01 a potentially effective option for this challenging condition.
Read more →TOVX▼ -5.5%on this news
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
Theriva™ Biologics announced the upcoming presentation of results from the Phase 1 trial of VCN-01 in refractory retinoblastoma at the ASCO Annual Meeting on May 31, 2025. The data will illustrate safety and clinical outcomes, with the trial showing a tolerable toxicity profile and encouraging responses in patients. Additionally, Theriva's senior management will participate in an investigator meeting to discuss topline data from the VIRAGE Phase 2b trial of VCN-01 in metastatic pancreatic cancer, aiming to refine clinical strategies for these indications.
Read more →TOVXTheriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results
Theriva Biologics reported strong operational highlights for Q1 2025, notably the success of its VCN-01 therapy in a Phase 2b trial for metastatic pancreatic cancer, achieving key survival and safety endpoints. The company also conducted a public offering that boosted its cash reserves significantly. Looking ahead, Theriva is focusing on scaling up manufacturing for VCN-01 and preparing for a Phase 3 trial. Moreover, while operational costs have decreased, expenses related to research and development are anticipated to rise as the company advances its trials.
Read more →TOVX▼ -20.6%on this news· ran to -35% by day 1
Theriva Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - -
Theriva Biologics reported positive operational highlights and financial results for Q1 2025. Their oncolytic virus, VCN-01, achieved primary efficacy and safety endpoints in the VIRAGE Phase 2b clinical trial for metastatic pancreatic ductal adenocarcinoma. The successful results pave the way for a proposed Phase 3 trial. Additionally, the company raised funds from a public offering, which bolsters its financial position into 2026.
Read more →TOVX▼ -20.6%on this news· ran to -35% by day 1
Theriva Biologics Announces Closing of $7.5 Million Public Offering
Theriva Biologics announced the successful closing of its public offering, raising approximately $7.5 million. The offering included 6,818,180 shares of common stock and warrants to purchase additional shares at a combined price of $1.10 each. The company plans to use the proceeds mainly for working capital and corporate purposes, including research and development. There are also potential plans for investments or acquisitions, although no specific commitments have been made yet.
Read more →TOVX▼ -40.4%on this news· ran to -62% by day 3shared move
Theriva Biologics Announces Pricing of $7.5 Million Public Offering ROCKVILLE, Md.
Theriva Biologics announced the pricing of its public offering, amounting to $7.5 million, which involves the sale of up to 6,818,180 shares of common stock and related warrants. The offering is priced at $1.10 per share and is expected to close on or about May 8, 2025, subject to closing conditions. Proceeds from the offering will be used for working capital, general corporate purposes, and potentially to invest in products or technologies, although no current commitments exist.
Read more →TOVX▼ -40.4%on this news· ran to -62% by day 3shared move
Theriva Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients - Patien
Theriva Biologics announced that its VCN-01 treatment, used alongside standard chemotherapy gemcitabine/nab-paclitaxel, achieved primary efficacy and safety endpoints in the VIRAGE Phase 2b clinical trial for metastatic pancreatic ductal adenocarcinoma. The trial showed improved overall survival and progression-free survival, especially among patients receiving two doses of VCN-01. Additionally, the treatment was noted to have a favorable safety profile, with only transient adverse events being reported. The findings are expected to facilitate discussions for a Phase 3 confirmatory trial.
Read more →TOVX▲ +11.4%on this news· ran to +31% by day 3
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Theriva Biologics announced the presentation of data from its Phase 1b/2a clinical trial of SYN-004 (ribaxamase) at the ESCMID Global Congress in Vienna. The study focuses on evaluating the safety and tolerability of SYN-004 in allogeneic hematopoietic cell transplant recipients. The trial is designed to assess the drug's ability to mitigate the negative impacts of IV beta-lactam antibiotics on the gut microbiome and potentially prevent acute graft-versus-host disease. Findings from this trial could enhance the understanding of SYN-004's therapeutic benefits in the targeted patient population.
Read more →TOVXTheriva Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastat
Theriva Biologics announced positive findings from the second meeting of the Independent Data Monitoring Committee regarding its VIRAGE Phase 2b clinical trial testing VCN-01 in combination with standard chemotherapy for newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). The committee reported that VCN-01 demonstrated a well-tolerated safety profile among patients, with adverse events being consistent with previous trials. Furthermore, the study expects to provide topline clinical data in Q2 2025, which could inform the setup of a potential Phase 3 trial with regulatory agencies later this year.
Read more →TOVXTheriva™ Biologics to Present at the 2025 NeauxCancer Conference
Theriva Biologics will present at the 2025 NeauxCancer Conference in New Orleans from March 27th-29th. The company's management is scheduled to speak during the Innovation track on March 28th, focusing on their advancements in oncology therapeutics. In addition to the presentation, management will be available for one-on-one meetings with interested investors. Theriva's research centers around new methods designed to effectively combat cancer and improve patient outcomes.
Read more →TOVXTheriva Biologics Reports Full-Year 2024 Operational Highlights and Financial Results - Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data
Theriva Biologics reported operational highlights and financial results for the full year of 2024, including the completion of enrollment in the Phase 2b VIRAGE trial of VCN-01 for metastatic pancreatic ductal adenocarcinoma (PDAC). They received Fast Track designation from the FDA for VCN-01 and both FDA and EMA guidance for future pivotal trials. The company reported a decrease in cash reserves but has sufficient runway into Q3 2025. Anticipated topline data from the trial is expected in Q2 2025, showing potential for advancement in PDAC therapies.
Read more →TOVXTheriva™ Biologics to Participate in the Q1 Investor Summit Virtual
Theriva Biologics (NYSE American: TOVX) has announced its participation in the Q1 Investor Summit Virtual, scheduled for March 11, 2025. Steve Shallcross, the CEO, and Manel Cascallo, PhD, General Director, will present the company's advancements in therapeutic development for cancer and related diseases. The involvement in this summit highlights the company's proactive approach in engaging with investors and showcasing its clinical-stage portfolio.
Read more →TOVXTheriva Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer Rockville, MD
Theriva Biologics announced positive outcomes from a Type D meeting with the FDA regarding the design of a Phase 3 study for VCN-01 combined with chemotherapy for metastatic pancreatic cancer. The FDA agreed with Theriva's proposed design and advised against expanding the current Phase 2b study into Phase 3. This guidance is expected to assist in planning the next steps for VCN-01's development. An additional meeting with the FDA will be held after completing the VIRAGE study to discuss the Phase 3 study protocol.
Read more →TOVX▼ -23.1%on this news
Theriva Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metas
Theriva Biologics announced its operational highlights and financial results for Q3 2024, revealing successful enrollment of 92 patients in its VIRAGE Phase 2b trial for VCN-01 in metastatic pancreatic cancer. The company received Orphan Medicinal Product and Rare Pediatric Disease Designations for VCN-01, indicating regulatory support for its development. Financially, Theriva reported increased general and administrative expenses and impairment charges due to a decline in stock price, but it anticipated moving forward to expand its clinical trials. The Spanish Government has awarded funding to aid in the manufacturing of VCN-01.
Read more →TOVXTheriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
Theriva Biologics has been selected as one of five finalists for Merck KGaA's EMEA Advance Biotech Grant, providing recognition in the biotech sector. During the upcoming BIO Europe 2024 in Stockholm, Dr. Manel Cascalló will present the company's lead candidate, VCN-01, which is being tested in a Phase 2b trial for metastatic pancreatic cancer. The grant program aims to support emerging biotech companies with funding and commercialization guidance. The winners will be announced on November 4, 2024, following presentations to a panel of judges.
Read more →TOVX▲ +5%on this news
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma Rockville, MD
Theriva Biologics has announced that the European Commission has granted orphan medicinal product designation to its lead candidate VCN-01 for treating retinoblastoma. This designation highlights the critical need for new treatment options for this rare eye cancer prevalent in children. VCN-01 is also recognized in the U.S. with orphan drug and rare pediatric disease designations. The company aims to refine its clinical strategy for VCN-01 in collaboration with leading experts and regulatory bodies worldwide.
Read more →TOVX▲ +44.4%on this news
Theriva Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients DSMC has rev
Theriva Biologics has announced a positive review outcome from the Data and Safety Monitoring Committee (DSMC) regarding its Phase 1b/2a clinical trial of SYN-004, aimed at preventing acute graft-versus-host disease in allogeneic hematopoietic cell transplant patients. The DSMC reviewed data from Cohort 2, which included 19 patients, and recommended advancing to Cohort 3. The promising results suggest that SYN-004, which degrades IV beta-lactam antibiotics, may enhance treatment outcomes while maintaining gut microbiome health. The study, ongoing at Washington University, aims to evaluate the drug's safety and effectiveness in a broader patient population.
Read more →TOVX▼ -13.9%on this news· ran to -46% by day 3
Theriva Biologics Announces Pricing of $2.5 Million Public Offering ROCKVILLE, Md.
Theriva Biologics announced the pricing of a public offering aimed at raising $2.5 million through the sale of over 1.4 million shares at $1.75 each. The proceeds will primarily support working capital and research efforts associated with its therapeutics for cancer and related diseases. The closing of the offering is anticipated on September 27, 2024, contingent on customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for this offering.
Read more →TOVX▼ -10%on this news· ran to -46% by day 3shared move
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Theriva Biologics has successfully completed patient enrollment for the VIRAGE Phase 2b clinical trial, which studies VCN-01 combined with standard chemotherapy for metastatic pancreatic cancer. A total of 92 evaluable patients were recruited across 15 sites in Spain and the USA within a span of 21 months. The enrollment is a significant achievement given the urgent need for effective therapies in this area. The company plans to engage with regulatory bodies to discuss future steps in the trial, including a potential interim data analysis.
Read more →TOVX▼ -10%on this news· ran to -46% by day 3shared move
Corporate Overview September 2024 2 FORWARD LOOKING STATEMENTS This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . In some cases forward -
Theriva Biologics provided an overview of its pipeline and forward-looking statements regarding VCN-01, an oncolytic virus targeting multiple cancers, including pancreatic ductal adenocarcinoma. VCN-01 is currently in a Phase 2b clinical trial and aims to combine with standard chemotherapy. The company emphasizes the ongoing development and potential regulatory benefits of its products, despite the uncertainties involved in clinical research and market competition. The presentation highlights the need for continued enrollment and successful trial execution to meet expectations.
Read more →TOVX▼ -5.2%on this news
Theriva Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program - Theriva Biologics and the Universitat Aut noma de Barcelona to receive a total of 2.28 Million to suppor
Theriva Biologics has been awarded 2.28 million euros from the Spanish government to support its THERICEL project in collaboration with the Universitat Autònoma de Barcelona. The funding includes a loan of 1.33 million euros for Theriva and a grant of 0.95 million euros for UAB, aimed at advancing a suspension cell platform for viral therapy manufacturing. This project endeavors to improve the efficiency and cost-effectiveness of producing adenoviral and AAV therapies, positioning Theriva as a leader in oncolytic virus development.
Read more →TOVXTheriva Biologics Announces Reverse Stock Split
Theriva Biologics, a clinical-stage biopharmaceutical company, has announced a reverse stock split at a ratio of 1-for-25 shares. This decision was approved by the Board of Directors to ensure compliance with the NYSE American's share price requirements. The reverse split will take effect on August 26, 2024, with shares starting to trade on a split-adjusted basis thereafter. The total number of outstanding shares will decrease significantly, from over 25 million to approximately 1 million, facilitating a more manageable shareholder structure.
Read more →TOVXTheriva Biologics Announces Reverse Stock Split Rockville, MD
Theriva Biologics, Inc. has announced a reverse stock split with a ratio of one share for every twenty-five shares, effective August 26, 2024. This action aims to satisfy the NYSE American's share price requirements and is expected to reduce the outstanding shares significantly. The Board of Directors authorized this split without needing shareholder approval, which could raise governance concerns. The company's stock will continue to trade under the ticker TOVX, but with a new CUSIP number post-split.
Read more →TOVXTheriva Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results - VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma
Theriva Biologics reported its operational highlights and financial results for Q2 2024, focusing on the VIRAGE Phase 2b trial of VCN-01 in combination with chemotherapy for metastatic pancreatic cancer. The company has received Fast Track and Rare Pediatric Disease Designations from the FDA for VCN-01, demonstrating regulatory support for its innovative treatment approach. As of June 30, 2024, the company has $16.6 million in cash, which is expected to support operations into the second quarter of 2025. However, an impairment charge of $4 million was recorded due to a decrease in the market value of the company’s stock, affecting its goodwill valuation.
Read more →TOVX▼ -16%on this news· ran to -30% by day 3
Theriva Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma Rockville, MD
Theriva Biologics has received Rare Pediatric Drug Designation from the U.S. FDA for VCN-01, which targets retinoblastoma. The designation underscores the urgent need for effective treatment options for pediatric patients suffering from this serious condition. Additionally, preliminary results from an investigator-sponsored Phase 1 trial evaluating VCN-01 have been deemed positive, indicating its potential as an adjunct therapy to chemotherapy. This designation may also make Theriva eligible for a Priority Review Voucher if their Biologics License Application progresses successfully.
Read more →TOVX▼ -8.6%on this news· ran to -23% by day 3
Theriva Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer Rockville, MD
Theriva Biologics has received Fast Track Designation from the FDA for its lead candidate VCN-01, aimed at treating metastatic pancreatic cancer. The designation facilitates quicker review and development due to the significant medical need in this area. The ongoing Phase 2b clinical trial, VIRAGE, is evaluating VCN-01 in combination with standard chemotherapy. The company is progressing towards completing patient enrollment by the third quarter of 2024, aiming to improve survival outcomes.
Read more →TOVXTheriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference
Theriva™ Biologics, a clinical-stage company focused on cancer therapeutics, will participate in the A.G.P. 2024 Virtual Healthcare Conference. The event will include a corporate update and a fireside chat scheduled for May 21, 2024, at 7:30 AM ET. The company is advancing a novel oncolytic adenovirus platform aimed at improving cancer treatment outcomes. This participation may enhance visibility among investors and the broader healthcare community.
Read more →TOVXTheriva Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory
Theriva Biologics has reported positive topline results from its Phase 1 trial of the oncolytic adenovirus VCN-01 for pediatric patients with refractory retinoblastoma. Additionally, the company has presented preclinical data highlighting the potential synergy of VCN-01 with liposomal irinotecan in pancreatic cancer treatments. The ongoing Phase 2b clinical trial, VIRAGE, is advancing as planned, with expected completion of enrollment in the third quarter of 2024. Financial results indicate a decrease in administrative expenses, alongside an increase in research and development costs, attributed to expanding clinical trials and initiatives.
Read more →TOVX▲ +11.2%on this news
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Theriva Biologics has announced that its Phase 2b clinical trial for VCN-01, in combination with standard chemotherapy for pancreatic ductal adenocarcinoma, has been accepted for presentation at the 2024 ASCO Annual Meeting. The trial aims to evaluate the efficacy of this combination therapy in newly-diagnosed metastatic patients. The presentation is scheduled for June 1, 2024, and will highlight the trial's design and significance in the treatment landscape for this challenging cancer type.
Read more →TOVX▼ -8.3%on this newsshared move
Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma -Phase 1 trial in collaboration with Sant Joan de D
Theriva Biologics has announced positive topline data from its investigator sponsored Phase 1 trial of intravitreal VCN-01, aimed at treating pediatric patients with refractory retinoblastoma. Conducted in collaboration with Sant Joan de D u-Barcelona Children's Hospital, the trial showed favorable safety and clinical outcomes, reinforcing VCN-01's therapeutic potential. Following the positive results, Theriva will obtain an exclusive worldwide license and related patents for VCN-01, highlighting its role in addressing the unmet needs in pediatric cancer treatment.
Read more →TOVXTheriva Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27 th Annual Meeting - Lea
Theriva Biologics announced that they will present preclinical data at the upcoming American Society for Cell and Gene Therapy meeting. This data highlights the enhanced anti-tumor effects of their product candidate VCN-01 in combination with liposomal irinotecan for treating human pancreatic cancer. The findings suggest a promising synergy with first-line chemotherapy regimens, with the company planning to evaluate additional combinations. The research contributes to their ongoing efforts targeted at improving treatment outcomes for pancreatic cancer patients.
Read more →TOVXCorporate Overview April 2024 2 FORWARD LOOKING STATEMENTS This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . In some cases forward - look
Theriva Biologics provided an overview of its strategies and developments as of April 2024. The company is advancing VCN-01, an oncolytic virus, in clinical trials for pancreatic cancer and other indications, while emphasizing the potential benefits of the drug alongside standard chemotherapy. Financially, Theriva maintains a robust cash reserve, supporting ongoing and future trials amidst a competitive landscape. The projections, however, come with caution, as many factors could impact clinical success and regulatory clearances.
Read more →TOVXTheriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
Theriva Biologics has announced its presentation of preclinical data on VCN-01 at the ASGCT 27th Annual Meeting. The data indicates a potential synergy between VCN-01 and liposomal irinotecan in treating pancreatic cancer. The presentation is part of the company’s ongoing efforts to explore combinations with various chemotherapy regimens, including gemcitabine and nab-paclitaxel. This highlights the company’s commitment to addressing unmet medical needs in oncology.
Read more →TOVX▼ -5%on this news
Theriva Biologics Reports Full-Year 2023 Operational Highlights and Financial Results - The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE , the Phase 2b clinical trial of VCN-01 in c
Theriva Biologics has reported its operational highlights and financial results for the year ended December 31, 2023. The independent data monitoring committee has recommended the continuation of the VIRAGE Phase 2b trial of VCN-01, indicating that there are no safety concerns. The company anticipates completing enrollment in this trial by the first half of 2024. Additionally, it has reported $23.2 million in cash, which will support its operations through early 2025.
Read more →TOVXTheriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
Theriva Biologics (TOVX) is set to host a conference call on March 25, 2024, at 8:30 a.m. ET, to discuss its financial performance for the year ended December 31, 2023, along with a corporate update. The company specializes in developing therapeutics targeting cancer and related diseases using innovative platforms. Individuals can participate in the live call and will also have access to the archived webcast. This event reflects the company's commitment to transparency and communication with investors and the public.
Read more →TOVXTheriva™ Biologics to Participate in the BIO-Europe Spring Conference
Theriva Biologics (NYSE American: TOVX) announced its participation in the BIO-Europe Spring Conference, scheduled for March 18-20, 2024, in Barcelona, Spain. The company will provide a corporate update and engage in one-on-one meetings during the event. Theriva is focused on developing therapeutics targeting cancer and related diseases, with a new oncolytic adenovirus platform among its advanced candidates. Presentations will occur at the Barcelona International Convention Centre, highlighting the company's commitment to addressing areas with high unmet medical needs.
Read more →TOVX▲ +14.6%on this news
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
Theriva Biologics announced a positive recommendation from the Independent Data Monitoring Committee for its Phase 2b clinical trial, VIRAGE, which evaluates the oncolytic adenovirus VCN-01 combined with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma. The IDMC's assessment indicated that the trial can proceed as planned without modifications, emphasizing the safety profile of VCN-01 and the feasibility of repeated dosing. The trial aims to enroll 92 participants and is expected to complete enrollment by mid-2024.
Read more →TOVX▲ +14.6%on this news
Theriva Biologics Announces Positive Recommendation
Theriva Biologics has received a positive recommendation from the Independent Data Monitoring Committee (IDMC) for its multinational Phase 2b clinical trial, VIRAGE, assessing VCN-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC). The trial will proceed with no changes to the protocol, and safety assessments have found no significant concerns. VCN-01's safety profile has remained consistent with previous evaluations, and the trial aims to complete enrollment by mid-2024. The outcome of this trial may impact treatment options for first-line metastatic PDAC patients.
Read more →TOVXTheriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference
Theriva Biologics, Inc. (TOVX) announced its participation in the B. Riley Securities Annual Oncology Conference on January 18, 2024. The company's management will engage in a fireside chat, highlighting their commitment to advancing cancer therapeutics. Theriva is developing a novel oncolytic adenovirus platform aimed at improving tumor responses and access to therapies. Their lead candidates focus on addressing critical areas in cancer treatment with the potential for significant patient benefit.
Read more →TOVXCorporate Overview 08 January 2024 2 FORWARD LOOKING STATEMENTS This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . In some cases forward -
Theriva Biologics has provided an overview of its operations, focusing on VCN-01, an optimized oncolytic virus for treating pancreatic cancer. The company is currently conducting a Phase 2b clinical trial for VCN-01 in combination with standard-of-care chemotherapy. Despite a promising pipeline and a solid financial position, there are significant risks and uncertainties related to trial completion and regulatory approvals that could affect future outcomes.
Read more →TOVX▼ -6.3%on this news· ran to -17% by day 3
Theriva Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results - VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma r
Theriva Biologics has reported its operational highlights and financial results for Q3 2023, emphasizing the progress of its Phase 2b clinical trial of VCN-01 in treating metastatic pancreatic ductal adenocarcinoma. The company is on track to complete enrollment for the trial in the first half of 2024, with safety data suggesting VCN-01 is well tolerated. At recent conferences, Theriva presented encouraging survival data indicating the potential for VCN-01 to enhance outcomes when combined with other therapies. The company maintained a financial position with $31.2 million in cash, providing a runway for continued development efforts.
Read more →TOVX▲ +7.2%on this news
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results
Theriva Biologics will hold a conference call on November 13, 2023, at 8:30 a.m. ET to discuss its third-quarter financial results and provide a corporate update. The company is focusing on developing therapeutics aimed at treating cancer and related diseases. Investors and the public can access the live call via telephone or through a webcast available on the company's website. The call underscores Theriva's commitment to transparency and communication with stakeholders.
Read more →TOVXTheriva™ Biologics to Participate in the BIO-Europe Conference
Theriva Biologics (TOVX) announced its participation in the BIO-Europe Conference scheduled for November 6-8, 2023, in Munich. During the conference, the company will provide a corporate update and conduct one-on-one meetings with interested parties. Theriva Biologics is focused on developing therapeutics to treat cancer and related diseases, with its pipeline including promising candidates like VCN-01.
Read more →TOVXE xhibit 99.1 Theriva Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ES
Theriva Biologics announced promising survival outcomes data from a Phase 1 study evaluating VCN-01 combined with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Presented at the ESMO Congress 2023, the data indicated enhanced survival correlated with increased CPS scores, a critical determinant for anti-PD-(L)1 therapies. The presentation highlighted VCN-01's unique mechanism of action and its potential to improve treatment responses over previous therapies.
Read more →TOVXTheriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023
Theriva™ Biologics announced encouraging survival outcomes from a Phase 1 study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Results presented at ESMO Congress indicate heightened patient survival correlating with increases in the CPS score from VCN-01 treatment. The data suggest that VCN-01 may help to overcome resistance to previous anti-PD-(L)1 therapies. A live webinar featuring expert oncologist Ricard Mesia, M.D., to discuss these findings will be held soon.
Read more →TOVXTheriva Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma
Theriva Biologics announced promising results from a Phase 1 study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma. The findings, to be presented at the ESMO Congress 2023, indicated encouraging survival outcomes, with a correlation observed between VCN-01 administration and overall patient survival. Despite a notable objective response rate of 0%, the study shows potential for VCN-01 in transforming treatment options in this high unmet medical need area. A key opinion leader webinar will further discuss these findings before the public presentation.
Read more →TOVXTheriva Biologics to Participate in the Emerging Growth Conference
Theriva Biologics (TOVX) will participate in the Emerging Growth Conference on October 4-5, 2023, to provide a corporate update and hold one-on-one investor meetings. The company's management will present details about their pipeline, including therapies aimed at treating cancer and related diseases. The webcast and replay of the presentation will be accessible through the conference portal and the company's website.
Read more →TOVXTheriva Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results - Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreati
Theriva Biologics has reported its operational highlights and financial results for Q2 2023, marking the initiation of dosing for U.S. sites involved in the VIRAGE Phase 2b trial of VCN-01 in combination with chemotherapy for pancreatic cancer. The therapy has shown a well-tolerated safety profile, and it has received Orphan Drug Designation from the U.S. FDA. The company aims to complete enrollment by the first quarter of 2024. However, it has also noted an increase in general administrative expenses and a decrease in cash reserves compared to the previous year.
Read more →TOVX▲ +5.7%on this news
Theriva Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - Initiated dosing at U.S. sites for VIRAGE - -S
Theriva Biologics has announced progress in its VIRAGE clinical trial, which is evaluating VCN-01 in combination with chemotherapy for pancreatic cancer. Dosing has commenced at U.S. sites, while patients in Spain have received their second doses of VCN-01, showing good tolerability. The trial is on track to complete enrollment by the first quarter of 2024, aiming to address the unmet medical needs of pancreatic ductal adenocarcinoma patients. VCN-01 has a unique action mechanism and has received Orphan Drug designations, hinting at its potential in this challenging field.
Read more →TOVXTheriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results
Theriva Biologics (NYSE American: TOVX) has announced a conference call scheduled for August 8, 2023, to discuss its financial results for the second quarter of 2023 and provide a corporate update. The company specializes in developing therapeutics aimed at treating cancer and related diseases. Their lead products include an oncolytic adenovirus platform and therapeutic candidates designed to improve patient outcomes in cancer treatment and related conditions. Investors and the public can access the call and the archived webcast through the company's website.
Read more →TOVX▲ +16.6%on this news· ran to +41% by day 3
Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer Rockville, MD
Theriva Biologics announced that its candidate VCN-01 has received orphan drug designation from the U.S. FDA for the treatment of pancreatic cancer. This designation highlights the urgent need for new therapies for patients suffering from pancreatic ductal adenocarcinoma, which has a low survival rate. The company is currently conducting the VIRAGE Phase 2b clinical trial to evaluate VCN-01's efficacy in combination with standard chemotherapy. VCN-01 aims to offer multiple antitumor effects by selectively targeting tumor cells while enhancing chemotherapy effectiveness.
Read more →TOVXTheriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery
Theriva Biologics has appointed Dr. Ramon Alemany as Senior Vice President of Discovery. Dr. Alemany, a recognized expert in oncolytic adenoviruses, will oversee the development pipeline and strengthen collaborations with the Catalan Institute of Oncology and the Biomedical Research Institute of Bellvitge. His leadership is expected to enhance the progress of Theriva's discovery program and expand therapeutic indications for its products.
Read more →TOVXTheriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results - Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chem
Theriva Biologics announced its first quarter 2023 operational highlights and financial results, emphasizing its continued enrollment in the VIRAGE Phase 2b trial for VCN-01, targeting pancreatic ductal adenocarcinoma. The company reported a cash balance of $36.1 million as of March 31, 2023, which provides a financial runway into the third quarter of 2024. Increased operational expenses have been noted, with general and administrative and research & development costs rising, alongside positive advancements in trials for both VCN-01 and SYN-004.
Read more →TOVX▲ +14%on this news
Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results
Theriva Biologics announced it will host a conference call on May 11, 2023, to discuss its first quarter 2023 financial results and provide a corporate update. The company focuses on developing therapeutics aimed at treating cancer and related diseases through innovative platforms. Key products include oncolytic adenoviruses and therapies aimed at preserving microbiome health in patients. Investors and the public can participate in the call and access an archived webcast on the company's website.
Read more →TOVX▲ +7.6%on this news
Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Theriva Biologics announced the presentation of data from Cohort 1 of its Phase 1b/2a clinical trial for SYN-004, aimed at preventing acute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients. The presentation will take place at the 33rd European Congress of Clinical Microbiology & Infectious Diseases, highlighting interim safety and pharmacokinetic findings. The trial involves a randomized, double-blinded design and is ongoing at Washington University School of Medicine. SYN-004 is designed to protect the gut microbiome during antibiotic treatment in these patients.
Read more →TOVXTheriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results - Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination w
Theriva Biologics reported operational highlights and financial results for Q4 and full year 2022, announcing the dosing of the first patient in the VIRAGE Phase 2b trial of VCN-01 for advanced pancreatic ductal adenocarcinoma. The company also initiated a Phase 1 trial of VCN-01 for brain tumors and shared positive data from the Phase 1b/2a trial of SYN-004. Financially, Theriva noted a cash balance of $41.8 million, sufficient to support its developmental efforts into Q3 2024, although it reported increases in both administrative and research expenses.
Read more →TOVXTheriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
Theriva Biologics has announced a rescheduling of its conference call to discuss the fourth quarter and full-year financial results for 2022. Originally set for March 27, 2023, the call will now take place on March 30, 2023, at 8:30 a.m. ET. The company aims to provide an update on its operational highlights and financial performance during this call, which can be accessed via telephone or online. Theriva Biologics continues to focus on developing therapeutics aimed at addressing cancer and unmet medical needs.
Read more →TOVXTheriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
Theriva Biologics, a clinical-stage biotech company, will hold a conference call on March 27, 2023, to discuss its financial results for the fourth quarter and full-year of 2022. The call aims to provide a corporate update, reflecting the company's focus on developing cancer therapies with high unmet needs. The company plans to share insights into its operational highlights during this session. Investors and the public can listen to the live and archived webcast via the company’s website.
Read more →TOVXTheriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - Data presented
Theriva Biologics announced promising data from a Phase 1b/2a trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients. The data, presented at the 2023 Tandem Meetings, suggest that SYN-004 is well-tolerated and may improve outcomes by addressing limitations of broad-spectrum IV beta-lactam antibiotics. The trial will evaluate additional cohorts to assess the benefits of SYN-004 in reducing serious adverse events associated with antibiotic use. Further updates are expected as dosing progresses into Cohort 2.
Read more →TOVX▲ +7.9%on this news
Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma -Initiation of Phase 2b trial follows c
Theriva Biologics has announced the dosing of the first patient in its VIRAGE Phase 2b clinical trial, which investigates VCN-01 combined with standard chemotherapy for treating metastatic pancreatic ductal adenocarcinoma. The trial, which has received clearance from the FDA and AEMPS, aims to enroll 92 adults at multiple sites across the US, Spain, and Germany. Primary endpoints will include overall survival and safety. This trial represents a significant step forward in addressing the unmet needs in treating this aggressive cancer type.
Read more →TOVX▲ +7.9%on this news
Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference
Theriva Biologics announced its participation in the B. Riley Securities 3rd Annual Oncology Conference, which will be held virtually on January 18-19, 2023. During the event, the company's management will provide a corporate update and participate in one-on-one investor meetings. The conference will include a presentation on January 19 at 1:30 PM ET that will be accessible to registered attendees via a webcast.
Read more →TOVX▲ +12.4%on this news· ran to +28% by day 1
Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors -Clinical trial is being conducted at St. Jame
Theriva Biologics has announced the dosing of the first patient in a Phase 1 clinical trial of VCN-01, an oncolytic adenovirus aimed at treating high-grade brain tumors. The trial, conducted at St. James's University Hospital in the UK in collaboration with the University of Leeds, seeks to evaluate the safety and effectiveness of VCN-01 when administered intravenously prior to surgical resection. If successful, this novel approach has the potential to revolutionize treatment by allowing for multiple administrations without the need for invasive surgery.
Read more →TOVXTheriva Biologics to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Co
Read more →TOVXTheriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results
-Conference call to be held on Friday, November 11 at 8:30 a.m. ET- ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and
Read more →TOVXTheriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results -Reported encouraging clinical data supporting the differentiated mode-of action of Theriva's novel oncolytic adenovirus (OV) plat
Reports Third Quarter 2022 Operational Highlights and Financial Results -Reported encouraging clinical data supporting the differentiated mode-of action of Theriva's novel oncolytic adenovirus (OV) platform- from the Federal Drug Administration (FDA) and Spanish Competent Auth
Read more →TOVXTheriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
- Initiation of Cohort 2 Follows a Positive Review of Safety and Pharmacokinetic (PK) Data from Cohort 1 by an Independent Data and Safety Monitoring Committee - - Cohort 2 Patient Dosing Highlights Momentum Across the Theriva Oncology-Focused Clinical Pipeline - ROCKVILLE, Md.
Read more →TOVXTheriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it
Read more →TOVXTheriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus Therapeutics
ROCKVILLE, Md., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today t
Read more →TOVX▼ -19.6%on this news
Theriva Biologics Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
ROCKVILLE, Md., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced a prese
Read more →TOVXSynthetic Biologics Rebrands as Theriva Biologics -Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administration - Rockville, MD
Synthetic Biologics Rebrands as Theriva Biologics -Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administration - MD, October 12, 2022 - Theriva Biologics, Inc. (NYSE American: TOVX), ("Theriva" or
Read more →TOVXSynthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma - Precli
Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma - Preclinical results demonstrated that topotecan treatment enha
Read more →TOVXSynthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The DSMC
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The DSMC has reviewed the safety and pharmacokinetic data from C
Read more →TOVXC o nc o m ita n t Se q u e nti al 1 2 p=0,022 Value K ep K ep marker T2 relaxation time (n=20) No differences. The percentile 25% of T2, was close to be statistically significant, (p - value =0.06349) DWI biomarkers (
0 - 1 C o nc o m ita n t Se q u e nti al 1 2 p=0,022 Value K ep K ep marker T2 relaxation time (n=20) No differences. The percentile 25% of T2, was close to be statistically significant, (p - value =0.06349) DWI biomarkers (n=16) (D* & D, perfusion & diffusion components, respect
Read more →TOVXSynthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carci
Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck -Treatment with VCN-01 in combi
Read more →TOVXSynthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results -Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of
Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results -Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds
Read more →TOVXSynthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock Rockville, MD.
Announces $3 Million Private Placement of Convertible Preferred July 29, 2022 - Synthetic Biologics, Inc.. (NYSE American: SYN) ("Synthetic Biologics" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high un
Read more →TOVXSynthetic Biologics Announces Reverse Stock Split Rockville, MD
Announces Reverse Stock Split July 15, 2022 - Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstandin
Read more →TOVXSynthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results -Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed public
Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results -Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and
Read more →TOVXOncolytic Adenovirus With Hyaluronidase Activity That Evades Neutralizing Antibodies And Allows Re - administration: VCN - 11 Ana Mato - Berciano , Maria V. Maliandi , Sara Morgado , Marti Farrera - Sal, Paz Moreno, Rafa
Oncolytic Adenovirus With Hyaluronidase Activity That Evades Neutralizing Antibodies And Allows Re - administration: VCN - 11 Ana Mato - Berciano , Maria V. Maliandi , Sara Morgado , Marti Farrera - Sal, Paz Moreno, Rafael Moreno, Luis A. Rojas, Gabriel Capell , Miriam Bazan - Pe
Read more →TOVXSynthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial -Orally administered SYN-020 observed to be well tolerated across all doses in he
Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending -Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, MD - May 10, 2022 (GLOBE NEWSWIRE) -- Synthet
Read more →TOVXSynthetic Biologics Announces Management Transitions in Support of Strategic Transformation -Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of
Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation -Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences- -Manel Cascall , Ph.D., appointed as G
Read more →TOVXSynthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results -Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblast
Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results -Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA- -As of December 31, 2021, Synth
Read more →TOVXSynthetic Biologics Completes Acquisition of VCN Biosciences - Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration - -Strong cash position to support mult
Synthetic Biologics Completes Acquisition of - Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous -Strong cash position to support multiple inflection points for VCN-01 with the start of a Phase 2 trial in combination with
Read more →TOVXJanuary 2022 B. Riley Securities Oncology Investor Conference Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 199
January 2022 B. Riley Securities Oncology Investor Conference Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, concerning Synthetic Biologics and VCN Bios
Read more →TOVXSynthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors Lead drug candidate VCN-01 demonstrated clini
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors Lead drug candidate VCN-01 demonstrated clinical activity in multiple Phase 1 clinical trials Design
Read more →TOVXSynthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Initiated a Phase 1 Multiple Ascending Dose Clinical Trial of SYN-020 in Healthy
Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM Initiated a Phase 1 Multiple Ascending Dose Clinical Trial of SYN-020 in Healthy Adult Volunteers; Topline Data Readout Expected in Q2 202
Read more →TOVXSynthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum The Company Encourages All Shareholders of Record Who Have Not Yet Voted to Do So by
Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum The Company Encourages All Shareholders of Record Who Have Not Yet Voted to Do So by October 13, 2021; Shareholders of Record May Vote Their Shares by Calling D.F. King &
Read more →TOVXSynthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum Rockville, MD
Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum September 21, 2021 - Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestin
Read more →TOVXSynthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Phase 1 Single-Ascending Dose Clinical Trial of SYN-020 Demonstrated Favorable
Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM Phase 1 Single-Ascending Dose Clinical Trial of SYN-020 Demonstrated Favorable Safety Profile and was Well Tolerated at All Dose Levels;
Read more →TOVXSynthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial Orally Administered SYN-020 Observed to be Well Tolerated in Healthy Volunteers; A Second Phase
Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Orally Administered SYN-020 Observed to be Well Tolerated in Healthy Volunteers; A Second Phase 1 Multiple-Ascending Dose Study is on Track to Begin in Q3 2021 MD, June 29
Read more →TOVXSynthetic Biologics Regains Compliance with NYSE American Continued Listing Standards Rockville, MD
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards Rockville, MD, May 26, 2021 - Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and t
Read more →TOVXSynthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD Initiated Phase 1a Sing
Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD Initiated Phase 1a Single-Ascending-Dose Clinical Trial of SYN-020 Intestinal
Read more →TOVXSynthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Rockville, MD
Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients MD, April 14, 2021 - Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging t
Read more →TOVXSynthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase A Multiple-Ascending Dose Study is on Track to Begin in Q3 2021 Phase 1 Clinical Program In
Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase Multiple-Ascending Dose Study is on Track to Begin in Q3 2021 1 Clinical Program Intended to Support Development of SYN-020 in Multiple Indications, Treatment
Read more →TOVXSynthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results -- Announced Washington University Has Begun Screening Patients for Enrollment in Phase 1b/2a Clinical Trial o f SYN-004 (ribaxamase)
Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results -- Announced Washington University Has Begun Screening Patients for Enrollment in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Read more →TOVXSynthetic Biologics Announces Extension of Compliance Plan Period by NYSE American Rockville, MD
Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American MD, November 24, 2020 - Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastr
Read more →TOVXSynthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors -- Dr. Monahan brings extensive drug development, clinical, regulatory, commercial and licensing experience -- Rockville, MD
Synthetic Biologics Welcomes Senior Biotech John Monahan, PhD, to Board of Directors -- Dr. Monahan brings extensive drug development, clinical, regulatory, commercial and licensing experience -- Rockville, MD, November 12, 2020 - Synthetic Biologics, Inc. (NYSE American: SY
Read more →TOVXSynthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results -- Received Notice from the FDA that the SYN-004 (ribaxamase) Phase 1b/2a Clinical Program in Adult Allogeneic HCT Recipients Ma
Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results -- Received Notice from the FDA that the SYN-004 (ribaxamase) Phase 1b/2a Clinical Program in Adult Allogeneic HCT Recipients May Proceed as Planned; Trial Commencement Anticipated in
Read more →TOVXSynthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients For Immediate Release Rockville, MD
Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients MD, October 2, 2020 - Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics desi
Read more →TOVXSynthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results -- Announced FDA Clearance of IND Application for SYN-020 Intestinal Alkaline Phosphatase (IAP) -- -- Signed Option License Agr
Synthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results -- Announced FDA Clearance of IND Application for SYN-020 Intestinal Alkaline Phosphatase (IAP) -- -- Signed Option License Agreement with Massachusetts General Hospital to Develop S
Read more →TOVXSynthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results -- Company Updates Guidance and Clinical Development Timeline in Response to the COVID-19 Global Pandemic -- -- Conference Call
Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results -- Company Updates Guidance and Clinical Development Timeline in Response to the COVID-19 Global -- Conference Call Today at 4:30 p.m. MD, May 5, 2020 - Synthetic Biologics, Inc. (NY
Read more →TOVXSynthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results -- Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT R
Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results -- Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT Recipients; Enrollment Expected in Q2 2020 -- -- Enroll
Read more →TOVXSynthetic Biologics Announces Acceptance of Compliance Plan by NYSE American Rockville, MD
Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American Rockville, MD, February 7, 2020 - Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat
Read more →TOVXSynthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients Rockville, MD
Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic Rockville, MD, January 7, 2020 - Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to dev
Read more →TOVXSynthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan Rockville, MD
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan Rockville, MD, November 27, 2019 - Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent
Read more →TOVXSynthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Conferen
Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Conference Call Today, November 4, 2019, at 4:30 p.m. (EST) --
Read more →TOVXSynthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results -- Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b/2a Clinical Trial of
Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results -- Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Tr
Read more →TOVXSynthetic Biologics Regains Compliance with NYSE American Continued Listing Standards For Immediate Release Rockville, MD
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards Rockville, MD, July 1, 2019 - Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the he
Read more →TOVXSynthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data
Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 -- -- Conference Call T
Read more →TOVXMarch 2019 Company Overview Updated 3.4.2019
March 2019 Company Overview Updated 3.4.2019 Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, on Synthetic Biologics' current expectations and projections
Read more →TOVXSynthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Reado
Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 -- -- Conference Call Wednes
Read more →TOVXSynthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C Rockville, MD
Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment Rockville, MD, January 03, 2019 - Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics de
Read more →TOVXSynthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development -- Single Phase 3 Clinical Trial May be Sufficient for Approval for Prevention of Antibiotic-Mediated
Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development Phase 3 Clinical Trial May be Sufficient for Approval for Prevention of Antibiotic-Mediated Clostridium difficile Infection (CDI) -- -- SYN-004 (ribaxamase)
Read more →TOVXSynthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results -- Announced Agreement with Cedars-Sinai Medical Center to Co-fund a Phase 2b Investigator-Sponsored Clinical Study of SYN-010,
Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results -- Announced Agreement with Cedars-Sinai Medical Center to Co-fund a Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Strengthened Balance S
Read more →TOVXSynthetic Biologics Prices $18,000,000 Public Offering Rockville, MD
Synthetic Biologics Prices $18,000,000 Public MD, October 11, 2018 - Synthetic Biologics, Inc. (NYSE American: SYN) ("Synthetic Biologics" or the "Company"), a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and res
Read more →TOVXSynthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator- Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- Co-funded Research to be Led by Dr. Mark Pimentel's Lab to
Synthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator- Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- Co-funded Research to be Led by Dr. Mark Pimentel's Lab to Further Evaluate the Efficacy and Safety of SYN-010 in
Read more →TOVXSynthetic Biologics Reports Second Quarter 2018 Operational Highlights and Financial Results - SYN-004 End of Phase 2 Meeting with U.S. Food & Drug Administration on Track for Third Quarter of 2018 - - Conference Call To
Synthetic Biologics Reports Second Quarter 2018 Operational Highlights and Financial Results - SYN-004 End of Phase 2 Meeting with U.S. Food & Drug Administration on Track for Third Quarter of 2018 - - Conference Call Today, August 8, 2018, at 4:30 p.m. (EDT) - Rockville, M
Read more →TOVXSynthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results - Preliminary Agreement Reached with FDA on Proposed Phase 3 Clinical Trial Synopsis for SYN-004 (ribaxamase) - - Conference Cal
Synthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results - Preliminary Agreement Reached with FDA on Proposed Phase 3 Clinical Trial Synopsis for SYN-004 (ribaxamase) - Conference Call Today, May 8, 2018, at 4:30 p.m. (EDT) - MD, May 8, 2
Read more →TOVXSynthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection Rockville, MD
Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Rockville, MD, April 23, 2018 - Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the micro
Read more →TOVXSynthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan For Immediate Release Rockville, MD
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan Rockville, MD, March 7, 2018 - Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restor
Read more →TOVXSynthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results - Company Provides Update on Late-stage Microbiome-focused Product Candidates - - Conference Call Today
Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results - Company Provides Update on Late-stage Microbiome-focused Product Candidates - - Conference Call Today, February 22, 2018, at 8:30 a.m. (EST) - MD, February 22, 2018 - Synthetic Biologic
Read more →TOVXBiotech Showcase 2018 Steven Shallcross - Interim CEO & CFO
Biotech Showcase 2018 Steven Shallcross - Interim CEO & CFO January 9, 2018 Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, on Synthetic Biologics' curr
Read more →TOVXSynthetic Biologics Announces Management Changes Rockville, MD
Synthetic Biologics Announces Management Rockville, MD, December 5, 2017 - Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Ste
Read more →TOVXSynthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results - Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs - - Held Initial Type-B Multidiscipl
Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results - Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs - Type-B Multidisciplinary Meeting with FDA to Discuss Late-Stage Clinical Advancement for
Read more →TOVXSynthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing For Immediate Release Rockville, MD
Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing Rockville, MD, September 12, 2017 - Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the he
Read more →TOVXSynthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results -- SYN-004 (ribaxamase) Receives Breakthrough Therapy Designation from FDA for Prevention of CDI -- -- Three Ribaxamase Present
Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results -- SYN-004 (ribaxamase) Receives Breakthrough Therapy Designation from FDA for Prevention of CDI -- Presentations to be Included at Infectious Disease Week (ID Week) 2017 -- -- Confe
Read more →TOVXSynthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) -- Allowance of Patent Provides Exclusive Method of Use P
Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) -- Allowance of Patent Provides Exclusive Method of Use Protection Until at Least 2034 -- Rockville, MD, June 2
Read more →TOVXSYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection -- FDA Action Marks First Breakthrough Therapy Designation for Clini
SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection -- FDA Action Marks First Breakthrough Therapy Designation for Clinical Program Designed to Prevent Primary Clostridium di
Read more →TOVXSynthetic Biologics Reports First Quarter
Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results - Results from Phase 2b Proof-of-Concept Study Exploratory Endpoints Demonstrate Ribaxamase Protects and Preserves Gut Microbiome from Ceftriaxone-mediated Dysbiosis - -- Two Ribaxam
Read more →TOVXPhase 2b Clinical Trial Results SYN - 004 (ribaxamase)
Phase 2b Clinical Trial Results SYN - 004 (ribaxamase) May 4, 2017 www.syntheticbiologics.com Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, on Syntheti
Read more →TOVXSynthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results -- Company Highlights Clinical Successes of Late-stage Microbiome-focused Programs, Plans for Phase 3 Development -- -- Conference Ca
Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results Highlights Clinical Successes of Late-stage Microbiome-focused Programs, Plans for Phase 3 Development Call Today, March 2, 2017, at 4:30 p.m. (EST) -- March 2, 2017 - Synthetic Biologics,
Read more →TOVXInvestor Presentation February 2017 Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, on Synthet
Investor Presentation February 2017 Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, on Synthetic Biologics' current expectations and projections about fu
Read more →TOVXSynthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA -- Enrollment in SYN-010 Pivotal Trial Will Be Open to All IBS-C Patients -- For Immediate Release Rockv
Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA -- Enrollment in SYN-010 Pivotal Trial Will Be Open to All IBS-C Patients -- Rockville, MD, January 18, 2017 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a la
Read more →TOVXBiotech Showcase Investor Presentation
2017 Biotech Showcase Investor Presentation January 9, 2017 Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, on Synthetic Biologics' current expectations
Read more →TOVXSynthetic Biologics' SYN-004 (ribaxamase)
Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI) - Presentation Planned for 9:30am (PT), Jan. 9, 2017 at Biotech Showcase in San Francisco - Rockville, MD, January 05, 2017 - Synthetic Biologics, Inc. (NY
Read more →TOVXAnnounces Commencement of Public Offering of Common Stock and Warrants
Announces Commencement of Public Offering of Common Stock and Warrants Rockville, MD, November 14, 2016 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that it has commenced an un
Read more →TOVXSynthetic Biologics Reports Third Quarter 2016 Operational Highlights and Financial Results - Completed Enrollment of Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection (CDI), Antibioti
Synthetic Biologics Reports Third Quarter 2016 Operational Highlights and Financial Results - Completed Enrollment of Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection (CDI), Antibiotic-Associated Diarrhea (AAD) and the Emergence of Antibi
Read more →TOVXSynthetic Biologics Reports Second Quarter 2016 Operational Highlights and Financial Results - Held End of Phase 2 Meeting with FDA and Received Guidance for Advancement to First Pivotal Trial for SYN-010, for the Treatm
Biologics Reports Second Quarter 2016 Operational Highlights and Financial Results Phase 2 Meeting with FDA and Received Guidance for Advancement to First Pivotal Trial for SYN-010, of Irritable Bowel Syndrome with Constipation (IBS-C) - Update on Enrollment for Phase 2b Proof
Read more →TOVXInvestor Slide Deck June 2016 Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, on Synthetic Bio
Investor Slide Deck June 2016 Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, on Synthetic Biologics' current expectations and projections about future e
Read more →TOVXMark Pimentel, MD, FRCP(C) Results from Two Phase 2 Clinical Trials of SYN - 010, a Proprietary, Modified - Release Formulation of Lovastatin Lactone Designed to Reduce Methane Production in the Gut to Treat an Underlyin
Mark Pimentel, MD, FRCP(C) Results from Two Phase 2 Clinical Trials of SYN - 010, a Proprietary, Modified - Release Formulation of Lovastatin Lactone Designed to Reduce Methane Production in the Gut to Treat an Underlying Cause of IBS - C. May 23, 2016 2 Forward - Looking Statem
Read more →TOVXSynthetic Biologics Reports First Quarter 2016 Operational Highlights and Financial Results -- Positioned to Initiate Phase 3 Clinical Trial for SYN-010 for the Treatment of Irritable Bowel Syndrome with Constipation (IB
Synthetic Biologics Reports First Quarter 2016 Operational Highlights and Financial Results -- Positioned to Initiate Phase 3 Clinical Trial for SYN-010 for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in 2H 2016 -- -- Two SYN-010 Posters Scheduled fo
Read more →TOVXInvestor Slide Deck March 2016 Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, on Synthetic Bi
Investor Slide Deck March 2016 Forward - Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, on Synthetic Biologics' current expectations and projections about future
Read more →TOVXSynthetic Biologics Reports 2015 Year End Operational Highlights and Financial Results -- Reported Positive Topline Data from Phase 2 Clinical Trials of SYN-010 for Irritable Bowel Syndrome with Constipation and SYN-004
Synthetic Biologics Reports 2015 Year End Operational Highlights and Financial Results -- Reported Positive Topline Data from Phase 2 Clinical Trials of SYN-010 for Irritable Bowel Syndrome with Constipation and SYN-004 for Prevention of C. difficile Infection and Antibiotic
Read more →TOVXInvestor Slide Deck January 11, 2016
Investor Slide Deck January 11, 2016 Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminolog
Read more →TOVXNew York City Microbiome Clinical Program Seminar
New York City Microbiome Clinical Program Seminar December 10, 2015 Introduction Jeff Riley, President & Chief Executive Officer Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections abo
Read more →TOVXSynthetic Biologics Reports Third Quarter 2015 Financial Results and Operational Highlights -- Initiated Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection and Antibiotic Associated Dia
Synthetic Biologics Reports Third Quarter 2015 Financial Results and Operational Highlights -- Initiated Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection and Antibiotic Associated Diarrhea -- -- Initiated Second Phase 2 Clinical Trial to
Read more →TOVXSynthetic Biologics Reports Second Quarter 2015 Financial Results and Operational Highlights - Achieved Planned Milestones for Company's Lead Microbiome Drug Candidates - - Enhanced Senior Management Team to Maximize Str
Synthetic Biologics Reports Second Quarter 2015 Financial Results and Operational Highlights - Achieved Planned Milestones for Company's Lead Microbiome Drug Candidates - - Enhanced Senior Management Team to Maximize Strategic Opportunities - - Strengthens Balance Sheet to
Read more →TOVXIntrexon and Synthetic Biologics Enter ECC to Develop Novel Biotherapeutics for Treatment of Phenylketonuria Collaboration Targets Delivery of an Essential Enzyme via ActoBiotics Platform without Adverse Impact on Gut Mi
Intrexon and Synthetic Biologics Enter ECC to Develop Novel Biotherapeutics for Treatment of Phenylketonuria Collaboration Targets Delivery of an Essential Enzyme via ActoBiotics Platform without Adverse Impact on Gut Microbiome GERMANTOWN, MD & ROCKVILLE, MD, August 10, 2
Read more →TOVXSynthetic Biologics Reports First Quarter 2015 Financial Results and Operational Highlights --Initiated Phase 2 for Prevention of C. difficile, Expected to Initiate Phase 2 for IBS-C by end of June 2015, and Expanded Lea
Synthetic Biologics Reports First Quarter 2015 Financial Results and Operational Highlights --Initiated Phase 2 for Prevention Expected to Initiate Phase 2 for IBS-C by end of June 2015, and Expanded Leadership Team as Company Moves into Next Development Stage -- -- Confer
Read more →TOVXSteven Shallcross Named Chief Financial Officer of Synthetic Biologics -- Executive Brings Significant Biotech Industry Leadership Experience to Team as Company Enters Next Phase of Development -- For Immediate Release R
Steven Shallcross Named Chief Financial Officer of Synthetic Biologics -- Executive Brings Significant Biotech Industry Leadership Experience to Team Next Phase of Development -- Rockville, MD, May 4, 2015 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen
Read more →TOVXMarch 2015 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - loo
March 2015 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such as "m
Read more →TOVXSynthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights -- Steady Progress in All Programs; Two Phase 2 Clinical Trials to Start in 2015 -- -- Conference Call Today
Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights -- Steady Progress in All Programs; Two Phase 2 Clinical Trials to Start in 2015 -- -- Conference Call Today, March 16, 2015, at 8:30 a.m. (ET) -- MD, March 16, 2015 - Synthetic Biologics
Read more →TOVXFebruary 2015 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward -
February 2015 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such as
Read more →TOVXJanuary 2015 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - l
January 2015 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such as
Read more →TOVXSynthetic Biologics Reports Third Quarter 2014 Financial Results and Operational Highlights -- Company Completes $18.9 Million Net Registered Direct Offering; Finalizes Plans for Start of Clinical Trials in C. difficile
Synthetic Biologics Reports Third Quarter 2014 Financial Results and Operational Highlights -- Company Completes $18.9 Million Net Registered Direct Offering; Finalizes Plans for Start of Clinical Trials in C. difficile and C-IBS -- -- Conference Call Today, November 14, 2
Read more →TOVXNovember 2014 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward -
November 2014 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such as
Read more →TOVXSynthetic Biologics to Raise $20.7 Million in Registered Direct Offering For Immediate Release Rockville, MD
Synthetic Biologics to Raise $20.7 Million in Registered Direct Offering Rockville, MD, October 10, 2014 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel biologics and drugs targeting specific pathogens that cause serious infections and di
Read more →TOVXSeptember 2014 NYSE MKT: SYN
September 2014 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such a
Read more →TOVXSynthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights -- Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C. difficile and C-IBS Programs i
Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights -- Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C-IBS Programs into the Clinic During 2014 -- -- Conference Call Today, August 14, 2014
Read more →TOVXMay 2014 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looki
May 2014 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such as "may
Read more →TOVXSynthetic Biologics Reports First Quarter 2014 Financial Results and Operational Highlights -- Conference Call Today
Biologics Reports First Quarter 2014 Financial Results and Operational Highlights -- Conference Call Today, May 15, 2014, at 8:30 a.m. (EDT) -- Rockville, MD, May 15, 2014 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candi
Read more →TOVXA Combination Trial of Estriol Plus Glatiramer Acetate in RRMS Rhonda Voskuhl, M.D. Professor, UCLA Dept. of Neurology Director, Multiple Sclerosis Program Jack H. Skirball Chair in MS Research Disclosures Author Disclos
A Combination Trial of Estriol Plus Glatiramer Acetate in RRMS Rhonda Voskuhl, M.D. Professor, UCLA Dept. of Neurology Director, Multiple Sclerosis Program Jack H. Skirball Chair in MS Research Disclosures Author Disclosure Information: R. Voskuhl: Synthetic Biologics Inc. licen
Read more →TOVXSynthetic Biologics Reports Year End 2013 Financial Results and Operational Update -- Conference Call Today
Synthetic Biologics Reports Year End 2013 Financial Results and Operational Update -- Conference Call Today, March 31, 2014, at 10:00 a.m. (EDT) -- Rockville, MD, March 31, 2014 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and dru
Read more →TOVXForward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events .
March 2014 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such as "m
Read more →TOVXSynthetic Biologics' Board of Directors Accepts Resignation of Long-Standing Founder and Board Member For Immediate Release Rockville, MD
Synthetic Biologics' Board of Directors Accepts Resignation of Long-Standing Founder and Board Member Rockville, MD, February 26, 2014 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that ca
Read more →TOVXJanuary 2014 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - l
January 2014 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such as
Read more →TOVXSynthetic Biologics Announces Proposed Public Offering of Common Stock Rockville, MD
Synthetic Biologics Announces Proposed Public Offering of Common Stock Rockville, MD, December 11, 2013 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced t
Read more →TOVXSynthetic Biologics and Intrexon Corporation
Synthetic Biologics and Intrexon Corporation Initiate Development of Novel Biologics for a Subset of Patients Suffering from Irritable Bowel Syndrome (IBS) - New Anti-Infective Program Underway Based on Innovative IBS Target - Rockville, MD, and Germantown, MD, December 9,
Read more →TOVXSynthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes -- Webcast to be held Monday, December 9 th at
Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes -- Webcast to be held Monday, December 9th at 9:00 a.m. EST -- Rockville, MD, December 7, 2013 - Synth
Read more →TOVXSynthetic Biologics Reports Third Quarter
Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update -- Conference Call Today, November 14, at 10 a.m. Eastern Time -- Rockville, MD, November 14, 2013 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the pre
Read more →TOVXSynthetic Biologics Initiates Manufacturing of SYN-004 for Use in Preclinical and Clinical Trials to Target the Prevention of C. difficile Infections -- Company's Proprietary Oral Beta-Lactamase Enzyme Successful Evaluat
Synthetic Biologics Initiates Manufacturing of SYN-004 for Use in Preclinical and Clinical Trials to Target the Prevention of C. difficile Infections -- Company's Proprietary Oral Beta-Lactamase Enzyme Successful Evaluation Conducted by FUJIFILM Diosynth Biotechnologies MD
Read more →TOVXNYSE MKT: SYN September 2013 Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward -
NYSE MKT: SYN September 2013 Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such a
Read more →TOVXSynthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update -- Progress Cited On Three Infectious Disease Programs, Including Two Programs in Collaboration with Intrexon Corporation; C. diffi
Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update -- Progress Cited On Three Infectious Disease Programs, Including Two Programs in Collaboration with Intrexon Corporation; C. difficile Prophylactic is Lead Anti-Infective Candidate --
Read more →TOVXNYSE MKT: SYN June 2013 Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - look
NYSE MKT: SYN June 2013 Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such as "ma
Read more →TOVXMay 20, 2013 NYSE MKT: SYN
May 20, 2013 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such as
Read more →TOVXSynthetic Biologics Reports First Quarter 2013 Financial Results For Immediate Release Rockville, MD
Synthetic Biologics Reports First Quarter 2013 Financial Results Rockville, MD, May 15, 2013 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the
Read more →TOVXMay 14, 2013 NYSE MKT: SYN
May 14, 2013 NYSE MKT: SYN Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such as
Read more →TOVXSynthetic Biologics Reports Year End
Synthetic Biologics Reports Year End 2012 Financial Results -- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- Rockville, MD, April 16, 2013 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focus
Read more →TOVXNYSE MKT: SYN
NYSE MKT: SYN February 11, 2013 Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology suc
Read more →TOVXNYSE MKT: SYN January 7, 2013
NYSE MKT: SYN January 7, 2013 Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such
Read more →TOVXSynthetic Biologics and Intrexon Corporation Initiate Development of Monoclonal Antibodies for Whooping Cough (Pertussis) -- The University of Texas at Austin to Join in Pertussis Research Efforts -- For Immediate Releas
Synthetic Biologics and Intrexon Corporation Initiate Development of Monoclonal Antibodies for Whooping -- The University of Texas at Austin to Join in Pertussis Research Efforts -- Rockville, MD, and San Francisco, CA, December 20, 2012 - Synthetic Biologics, Inc. (NYSE MK
Read more →TOVXNYSE MKT: SYN December 2012 Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward -
NYSE MKT: SYN December 2012 Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such as
Read more →TOVXSynthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program For Immediate Release Rockville, MD
Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program MD, December 3, 2012 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that th
Read more →TOVXSynthetic Biologics Reports Third Quarter 2012 Financial Results -- Accelerating Development of Product Candidates to Address Serious Infectious Diseases -- For Immediate Release Rockville, Md.
Synthetic Biologics Reports Third Quarter 2012 Financial Results Accelerating Development of Product Candidates to Address Serious Infectious Diseases -- Rockville, Md., November 14, 2012 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and inno
Read more →TOVXSynthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program -- Novel Oral Biologic Designed to Protect Patients from C. difficile Infection Associated with Systemic Antibiotics -- For Immediate
Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program -- Novel Oral Biologic Designed to Protect Patients from C. difficile Infection Associated with Systemic Antibiotics MD, November 12, 2012 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a dev
Read more →TOVXSynthetic Biologics Completes $10.8 Million Private Placement Financing For Immediate Release Rockville, MD
Synthetic Biologics Completes $10.8 Million Private Placement Financing MD, October 31, 2012 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, announced today the successful co
Read more →TOVXSynthetic Biologics Reports Second Quarter 2012 Financial Results -- Addition of Monoclonal Antibodies for Infectious Diseases Emphasizes Focus on Synthetic Biologics -- For Immediate Release Ann Arbor, MI
Synthetic Biologics Reports Second Quarter 2012 Financial Results -- Addition of Monoclonal Antibodies for Infectious Diseases Emphasizes Focus on Synthetic Biologics -- Ann Arbor, MI, August 14, 2012 - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biol
Read more →TOVXSynthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases -- Collaboration Harnesses Monoclonal Antibodies to Address Unmet Medical Needs -- -- Joint Confe
Synthetic Biologics and Intrexon Corporation Worldwide Exclusive Collaboration for -- Collaboration Harnesses Monoclonal Antibodies to Address Unmet Medical Needs -- -- Joint Conference Call Scheduled for Today, Wednesday, August 8, 2012 at 5:00pm(ET)/2:00pm(PT) -- Rockvill
Read more →TOVXSynthetic Biologics Reports First Quarter 2012 Financial Results -- Preclinical and Clinical Programs Moving Forward -- For Immediate Release Ann Arbor, MI
Synthetic Biologics Reports First Quarter 2012 Financial Results -- Preclinical and Clinical Programs Moving Forward -- Ann Arbor, MI, May 15, 2012 - Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying
Read more →TOVXSynthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman For Immediate Release Ann Arbor, MI
Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman Ann Arbor, MI, May 11, 2012 - Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today th
Read more →TOVXNYSE Amex: SYN
NYSE Amex: SYN April 24, 2012 Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics' current expectations and projections about future events . In some cases forward - looking statements can be identified by terminology such
Read more →TOVXSynthetic Biologics Reports 2011 Year End Financial Results -- Company Prioritizes Focus on Synthetic DNA-Based Therapeutics -- For Immediate Release Ann Arbor, MI
Synthetic Biologics Reports 2011 Year End Financial Results -- Company Prioritizes Focus on Synthetic DNA-Based Therapeutics -- Ann Arbor, MI, March 30, 2012 - Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-
Read more →TOVXv302228_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
v302228_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
Read more →TOVXAdeona Appoints C. Evan Ballantyne as Chief Financial Officer -- Former CFO of Clinical Data, Inc. Brings Extensive Financial Background to Emerging Synthetic Biologics Company -- For Immediate Release Ann
Adeona Appoints C. Evan Ballantyne as Chief -- Former CFO of Clinical Data, Inc. Brings Extensive Financial Background to Emerging Synthetic Biologics Company -- February 7, 2012 - Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN - News), a developer of synthetic DNA-based therap
Read more →TOVXAdeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus -- Adeona Chairman, Jeff Riley, Appointed New CEO; James S. Kuo to Remain
Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus -- Adeona Chairman, Jeff Riley, Appointed James S. Kuo to Remain on Board; Scott L. Tarriff and Nelson K. Stacks Join Board --
Read more →TOVXAdeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension For Immediate Release Ann Arbor, MI, & Germantown, MD
Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension Ann Arbor, MI, & Germantown, MD, November 21, 2011 - Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative disea
Read more →TOVXUnassociated Document Adeona Reports Third Quarter 2011 Financial Results -- Clinical Trial for Cognitive Dysfunction in Multiple Sclerosis Recruiting Patients -- For Immediate Release Ann Arbor, MI
Adeona Reports Third Quarter 2011 Financial Results -- Clinical Trial for Cognitive Dysfunction in Multiple Sclerosis Recruiting Patients -- Ann Arbor, MI, November 14, 2011 - Adeona Pharmaceuticals, Inc. (AMEX:AEN - News), a developer of innovative medicines for serious centra
Read more →TOVXUnassociated Document Adeona Appoints Jeff Lucero Riley as Independent Chairman For Immediate Release Ann Arbor, MI
Adeona Appoints Jeff Lucero Riley as Independent Chairman Ann Arbor, MI, November 2, 2011 - Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN - News), is pleased to announce the appointment of Jeff Riley, to serve as its independent, non-executive Chairman of the Board. Mr. Riley has
Read more →TOVXUnassociated Document Adeona Reports Second Quarter 2011 Financial Results -- Planning to Initiate Three New Clinical Trials Under INDs -- -- Revenues Increase at Adeona Clinical Laboratory -- -- reaZin TM and wellZin TM
Adeona Reports Second Quarter 2011 Financial Results -- Planning to Initiate Three New Clinical Trials Under INDs -- -- Revenues Increase at Adeona Clinical Laboratory -- -- reaZinTM and wellZinTM Commercialization Efforts Moving Forward -- Ann Arbor, MI, August 15, 2011 - Ad
Read more →TOVXAdeona Reports 1st Quarter 2011 Financial Results -- Adeona Clinical Laboratory, a Wholly Owned Subsidiary, Achieves Profitability -- -- Trimesta TM Clinical Trial Receives $2 Million in New Grant Funding -- -- reaZin TM
Adeona Reports 1st Quarter 2011 Financial Results -- Adeona Clinical Laboratory, a Wholly Owned Subsidiary, Achieves Profitability -- -- TrimestaTM Clinical Trial Receives $2 Million in New Grant Funding -- -- reaZinTM Commercialization Moving Forward -- Ann Arbor, MI, May 16
Read more →TOVXAdeona Executes Manufacturing and Supply Agreement with TG United for reaZin TM - Contract Provides Commercial-Scale Manufacturing Capabilities of Company's Zinc-Based Product Candidate for the Dietary Management of Alzh
Adeona Executes Manufacturing and Supply Agreement with TG United for reaZinTM - Contract Provides Commercial-Scale Manufacturing Capabilities of Company's Zinc-Based Product Candidate for the Dietary Management of Alzheimer's Disease and Mild Cognitive Impairment - Ann Arbor,
Read more →TOVXAdeona's Clinical Study of reaZin TM Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper -- Secondary Outcome of reaZin Treatment Supports Cognitive Benefit Versus Placebo -- -- Conference Ca
Adeona's Clinical Study of reaZinTM Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper -- Secondary Outcome of reaZin Treatment Supports Cognitive Benefit Versus Placebo -- -- Conference Call Scheduled for Friday, April 15, 2011 at 2:00 p.m. (EDT)
Read more →TOVXUnassociated Document Adeona to Raise $3.5 Million in Registered Direct Offering For Immediate Release Ann Arbor, MI
Adeona to Raise $3.5 Million in Registered Direct Offering Ann Arbor, MI, April 7, 2011 - Adeona Pharmaceuticals, Inc. (AMEX:AEN - News), a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement for the sa
Read more →TOVXUnassociated Document Adeona Reports 2010 Year End Financial Results -- $3.2 Million Net Revenues Reported for the Year Ended
Adeona Reports 2010 Year End Financial Results -- $3.2 Million Net Revenues Reported for the Year Ended December 31, 2010 -- -- Investor Conference Call Scheduled for 4:30pm (EDT) Today -- Ann Arbor, MI, March 31, 2011 - Adeona Pharmaceuticals, Inc. (AMEX:AEN - News), a develo
Read more →TOVXAdeona to Raise $4 Million in Registered Direct Offering For Immediate Release Ann Arbor, MI
to Raise $4 Million in Registered Direct Offering Arbor, MI, January 28, 2011 - Adeona Pharmaceuticals, Inc. (AMEX:AEN - News), a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement for the sale of ap
Read more →TOVXv207771_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
v207771_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
Read more →TOVXAdeona Announces Third Quarter 2010 Financial Results and Achievements Ann Arbor, MI
Announces Third Quarter 2010 Financial Results and Achievements Ann Arbor, MI, November 15, 2010 - Adeona Pharmaceuticals, Inc. (AMEX:AEN - News), a developer of innovative medicines for serious central nervous system diseases, announced today its third quarter 2010 financial
Read more →TOVXAdeona Announces Second Quarter 2010 Profitability and Achievements Company Achieves $979,782 Second Quarter Net Income
Announces Second Quarter 2010 Profitability and Achievements Achieves $979,782 Second Quarter Net Income ARBOR, MI - August 16, 2010 - Adeona Pharmaceuticals, Inc. (AMEX:AEN - News) announced today its second quarter 2010 financial results and recent will hold a conference ca
Read more →TOVXAdeona Announces Equity Financing and Clinical Update Ann Arbor, MI
Adeona Announces Equity Financing and Clinical Update Ann Arbor, MI - July 6, 2010 - Adeona Pharmaceuticals, Inc., (AMEX:AEN - News) announced today that on July 2, 2010, it completed an equity financing of $1 million with a single institutional investor, Seaside 88, L.P. The fi
Read more →TOVXAdeona Completes a $17.5 Million Corporate Partnership with Meda AB for the Development and Commercialization of Flupirtine for Fibromyalgia Adeona to Receive Royalties on Potential Billion Dollar Indication Meda to Assu
Adeona Completes a $17.5 Million Corporate Partnership with Meda AB for the Development and Commercialization of Flupirtine for Fibromyalgia Adeona to Receive Royalties on Potential Billion Dollar Indication Meda to Assume All Future Development Costs ANN ARBOR, MI - May 7, 2
Read more →TOVXAdeona Announces Fourth Quarter 2009 Results and Achievements Investor Call Scheduled for 9:00 AM EDT ANN ARBOR, MI- Adeona Pharmaceuticals, Inc. (AMEX: AEN - News ), a specialty pharmace
Adeona Announces Fourth Quarter 2009 Results and Achievements Investor Call Scheduled for 9:00 AM EDT ANN ARBOR, MI- Adeona Pharmaceuticals, Inc. (AMEX: AEN - News), a specialty pharmaceutical company developing new medicines for serious central nervous system diseases announce
Read more →TOVXAdeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President Company Intends to Launch and Establish Corporate Partnerships for its Products Ann Arbor, MI
Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President Company Intends to Launch and Establish Corporate Partnerships for its Products Ann Arbor, MI, February 9, 2010, Adeona Pharmaceuticals, Inc., (AMEX:AEN - News), announced today that it has appointed Jam
Read more →TOVXPOWERPOINT PRESENTATION ex99_1.htm AMEX: AEN OneMedForum 2010
Forward Looking Statements the leader addressing subclinical zinc deficiency chronic copper toxicity Copyright 2008 Pipex Pharmaceuticals, Inc. Copyright 2008 Pipex Pharmaceuticals, Inc. NYSE-Amex Listed: AEN $6MM Personally Invested by Chairman Went Public October 2006
Read more →TOVXAdeona Completes HartLab Acquisition ANN ARBOR, MI--(MARKET WIRE)
Adeona Completes HartLab Acquisition ANN ARBOR, MI--(MARKET WIRE)-July 13, 2009 -- Adeona Pharmaceuticals, Inc. (AMEX:AEN - News), a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of subclinical zinc deficiency and chronic coppe
Read more →TOVXAdeona Announces Appointment of Max Lyon as Chief Executive Officer and President Ann Arbor, Michigan
Announces Appointment of Max Lyon as Chief Executive Officer and Arbor, Michigan, June 29, 2009 -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a specialty pharmaceutical company dedicated to the awareness, prevention and treatment of subclinical zinc deficiency and chronic coppe
Read more →TOVXThis release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "p
Executes Agreement to Acquire Hartlab, a Chicago-Area CLIA-Certified Clinical Intended to Complete June 30, 2009 ARBOR, MI--(MARKET WIRE)-June 1, 2009 -- Adeona Pharmaceuticals, Inc. specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatm
Read more →TOVXAdeona Pharmaceuticals Announces First Quarter 2009 Results Ann Arbor, Michigan
Pharmaceuticals Announces First Quarter 2009 Results Arbor, Michigan, May 15, 2009 -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a specialty pharmaceutical company dedicated to the awareness, prevention and treatment of subclinical zinc deficiency and chronic copper toxicity i
Read more →TOVXAdeona Announces Acquisition of Colwell Clinical Laboratories, a Southern California CLIA-Certified Clinical Lab Acquisition Intended to Complete and Initiate Generating Revenues During the Current Quarter Regional and N
Announces Acquisition of Colwell Clinical Laboratories, a Southern California CLIA-Certified Clinical Lab Intended to Complete and Initiate Generating Revenues During the Current and National Growth Intended as First Clinical Lab Dedicated to the Diagnosis and Treatment of Di
Read more →TOVXAdeona Pharmaceuticals Announces Stock Repurchase Program Ann Arbor, Michigan
Pharmaceuticals Announces Stock Repurchase Program Arbor, Michigan, April 7, 2009 -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a specialty pharmaceutical company dedicated to the awareness, prevention and treatment of subclinical zinc deficiency and chronic copper toxicity in
Read more →TOVXAdeona Pharmaceuticals Announces Fourth Quarter and Year End 2008 Results 68% Reduction in Cash Used in Operations Ann Arbor, Michigan
Pharmaceuticals Announces Fourth Quarter and Reduction in Cash Used in Operations Arbor, Michigan, March 31, 2009 -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a specialty pharmaceutical company dedicated to the awareness, prevention and treatment of subclinical zinc deficienc
Read more →TOVXAdeona Pharmaceuticals Announces Clinical Update and Third Quarter 2008 Results Ann Arbor, Michigan
Adeona Pharmaceuticals Announces Clinical Update and Third Quarter 2008 Results Ann Arbor, Michigan, November 14, 2008 -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a pharmaceutical company developing innovative late-stage drug candidates for the treatment of autoimmune and centr
Read more →TOVXPipex Pharmaceuticals Announces Clinical Update and Second Quarter 2008 Results 43% Reduction in Quarterly Cash Operating Expenses Conference Call Thursday
Pipex Pharmaceuticals Announces Clinical Update and Second Quarter 2008 Results 43% Reduction in Quarterly Cash Operating Expenses Conference Call Thursday, August 14, 2008 at 4:30 p.m. EST Ann Arbor, Michigan, August 14, 2008 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a speci
Read more →TOVXPipex Pharmaceuticals Announces Results of Eighty Patient, Six Month, Prospective, Randomized, Double-Blind Clinical Trial of Oral Zinthionein for Dry Age-Related Macular Degeneration (AMD) Highly Statistically Significa
Pipex Pharmaceuticals Announces Results of Eighty Patient, Six Month, Prospective, Randomized, Double-Blind Clinical Trial of Oral Zinthionein for Dry Age-Related Macular Degeneration (AMD) Highly Statistically Significant Improvement in Visual Acuity (p 0.0001), Contrast Sens
Read more →TOVXPipex Pharmaceuticals Appoints Co-Founder and Vice Chairman Nicholas Stergis as Chief Executive Officer Ann Arbor, Michigan
Pipex Pharmaceuticals Appoints Co-Founder and Vice Chairman Nicholas Stergis as Chief Executive Officer Ann Arbor, Michigan, July 8, 2008 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatm
Read more →TOVXPipex Pharmaceuticals Announces Clinical Update and First Quarter 2008 Results Conference Call Thursday
Pipex Pharmaceuticals Announces Clinical Update and First Quarter 2008 Results Conference Call Thursday, May 15, 2008 at 4:30 p.m. EST Ann Arbor, Michigan, May 15, 2008 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stag
Read more →TOVXPipex Pharmaceuticals Announces Fourth Quarter and Year End 2007 Results Webcast/Conference Call Monday
Pipex Pharmaceuticals Announces Fourth Quarter and Year End 2007 Results Webcast/Conference Call Monday, March 31, 2008 at 5:00 p.m. EST Ann Arbor, Michigan, March 31, 2008 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-
Read more →TOVXPipex Pharmaceuticals Completes Type A Meeting with FDA for Oral Tetrathiomolybdate New Drug Application Company to Host Conference Call at 9:00 am Eastern Time Today Ann Arbor, Michigan
Pipex Pharmaceuticals Completes Type A Meeting with FDA for Oral Tetrathiomolybdate New Drug Application Company to Host Conference Call at 9:00 am Eastern Time Today Ann Arbor, Michigan, February 29, 2008 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical co
Read more →TOVXPipex Pharmaceuticals Anti-Copper COPREXA Demonstrates 40% Reduction of Insoluble Amyloid Beta in Animal Models of Alzheimer s Disease Results Presented at Neuroscience 2007 Annual Meeting in San Diego First Evidence of
Pipex Pharmaceuticals Anti-Copper COPREXA Demonstrates 40% Reduction of Insoluble Amyloid Beta in Animal Models of Alzheimer s Disease Results Presented at Neuroscience 2007 Annual Meeting in San Diego First Evidence of a Disease Modifying Effect in AD by a Drug Candidate Speci
Read more →TOVXPipex Pharmaceuticals Appoints David A. Newsome, M.D. as Chief Scientific Officer Pioneer of Zinc Therapy for Age-Related Macular Degeneration and Inventor of Zinc-Monocysteine Joins Senior Management Team
Pipex Pharmaceuticals Appoints David A. Newsome, M.D. as Chief Scientific Officer Pioneer of Zinc Therapy for Age-Related Macular Degeneration and Inventor of Zinc-Monocysteine Joins Senior Management Team ANN ARBOR, Michigan, October 15, 2007 -- Pipex Pharmaceuticals, Inc. (AM
Read more →TOVXPipex Pharmaceuticals Receives Equipment Loan from Bank of Ann Arbor Supports Pipex s New cGMP Pharmaceutical Manufacturing Facility in Ann Arbor Michigan Ann Arbor, Michigan
Pipex Pharmaceuticals Receives Equipment Loan from Supports Pipex s New cGMP Pharmaceutical Manufacturing Facility in Ann Arbor Michigan Ann Arbor, Michigan, October 3, 2007 -- Pipex Pharmaceuticals, Inc. ( Pipex ) (AMEX: PP), a specialty pharmaceutical company developing innov
Read more →TOVXPipex Pharmaceuticals Plans November NDA Filing for COPREXA Based on Pre-NDA Meetings with FDA Ann Arbor, Michigan
Pipex Pharmaceuticals Plans November NDA Filing for COPREXA Based on Pre-NDA Meetings with FDA Ann Arbor, Michigan, September 21, 2007 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatmen
Read more →TOVXPipex Pharmaceuticals Acquires Late-Stage Oral Candidate for Dry Age-Related Macular Degeneration (AMD) 80 Patient Double-Blind Clinical Trial Demonstrated Statistically Significant Improvement in Visual Acuity and Other
Pipex Pharmaceuticals Acquires Late-Stage Oral Candidate for Dry Age-Related Macular 80 Patient Double-Blind Clinical Trial Demonstrated Statistically Significant Improvement in Visual Acuity and Other Clinical Parameters of Dry AMD ANN ARBOR, MI, July 10, 2007 -- Pipex Phar
Read more →TOVXPipex Pharmaceuticals to begin Trading Today on the American Stock Exchange
Pipex Pharmaceuticals to begin Trading Today on the American Stock Exchange ANN ARBOR, MI June 26, 2007 -- Pipex Pharmaceuticals, Inc. ("Pipex") (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage oral drug candidates for the treatment of neurologic a
Read more →TOVXPipex Pharmaceuticals Announces Fourth Quarter and Year End 2006 Results Webcast/Conference Call Monday, April 2 nd at 8:30 a.m. EST Ann Arbor, Michigan
Pipex Pharmaceuticals Announces Fourth Quarter and Year End 2006 Results Webcast/Conference Call Monday, April 2nd at 8:30 a.m. EST Ann Arbor, Michigan, April 2, 2007 -- Pipex Pharmaceuticals, Inc. (OTC BB: PPXP), a specialty pharmaceutical company developing innovative late-st
Read more →TOVXPipex Pharmaceuticals, Inc. Announces the Appointment of Daniel J. Dorman and James S. Kuo, M.D., M.B.A. to the Board of Directors Ann Arbor, Michigan
Pipex Pharmaceuticals, Inc. Announces the Appointment of Daniel J. Dorman and James S. Kuo, M.D., M.B.A. to the Board of Directors Ann Arbor, Michigan, February 20, 2007 -- Pipex Pharmaceuticals, Inc. (OTC BB: PPXP), a specialty pharmaceutical company developing innovative late-
Read more →TOVXPipex Pharmaceuticals Completes $13.7 Million in Private Equity Financings Ann Arbor, Michigan
Pipex Pharmaceuticals Completes $13.7 Million in Private Equity Financings Ann Arbor, Michigan, November 28, 2006 Sheffield Pharmaceuticals, Inc. d/b/a Pipex Pharmaceuticals, Inc. (the Company ) (OTCBB: SFPH) and its wholly owned subsidiary, Pipex Therapeutics, Inc., a specialt
Read more →TOVXPipex Therapeutics' COPREXA Pivotal Clinical Trial Results Presented at NIH-Sponsored Wilson's Disease Association Conference Primary Endpoint Achieved, a Statistically Significant Reduction (p 0.05) in Neurologic Worsen
Therapeutics' COPREXA Pivotal Clinical Trial Results Presented at NIH-Sponsored Wilson's Disease Association Conference Endpoint Achieved, a Statistically Significant Reduction (p<0.05) in Neurologic Worsening Compared to Copper Chelator Trientine Arbor, Michigan, November 7,
Read more →Competitive Position
How TOVX ranks across every disease it competes inCompetitive Position is a premium feature
See how TOVX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial